Conclusions: Considerations regarding SERMs

Area of Science:

• Pharmacology and Toxicology
• Oncology
• Clinical Trial Design

Background:

• Selective estrogen receptor modulators (SERMs) are under investigation for disease prevention and treatment.
• Concerns exist regarding SERM carcinogenicity and efficacy, particularly when extrapolating from animal models to humans.
• The precise molecular and cellular mechanisms of SERM action remain incompletely understood.

Purpose of the Study:

• To address critical considerations and unresolved questions surrounding the clinical application of SERMs.
• To evaluate the discrepancies between preclinical data and human outcomes for SERMs.
• To discuss the challenges in SERM research, including semantic inconsistencies and optimal clinical trial design.

Main Methods:

• Review and synthesis of existing research on SERM carcinogenicity, efficacy, and mechanisms of action.
• Analysis of inconsistencies between animal and human data, and between epidemiological and randomized trial data.
• Discussion of the role of "occult cancers" in SERM efficacy and the need for validated surrogate markers.

Main Results:

• Inconsistencies in SERM efficacy and toxicity (carcinogenicity) between animal models and humans necessitate careful clinical evaluation.
• The cellular mechanisms of SERMs are not fully elucidated, impacting the interpretation of their actions.
• Discrepancies exist in understanding estrogen's role in cardiovascular disease and SERM effects.

Conclusions:

• The clinical utility of SERMs, especially in disease prevention for healthy individuals, requires further rigorous investigation due to inconsistent preclinical and clinical findings.
• Standardization of semantics and robust clinical trial designs, such as large, simple randomized trials, are crucial for advancing SERM research and application.
• Extrapolation of clinical trial results to practice necessitates careful consideration of statistical significance and clinical relevance.